Treatment and overall survival in renal cell carcinoma: A Swedish population-based study (2000-2008)

British Journal of Cancer

Volumn 108, Issue 7, 2013, Pages 1541-1549

  Wahlgren, T ^a   Harmenberg, U ^b   Sandstrom P ^b   Lundstam, S ^c   Kowalski, J ^d   Jakobsson, M ^a   Sandin, R ^a   Ljungberg, B ^e  

^a PFIZER INC   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d JK Biostatistics AB   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; SORAFENIB; SUNITINIB;

ADULT; ARTICLE; CANCER REGISTRY; CANCER THERAPY; FEMALE; GENDER; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; SWEDEN;

AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SWEDEN; TREATMENT OUTCOME;

EID: 84876460519     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.119     Document Type: Article

References (25)

1. Aron M, Nguyen MM, Stein RJ, Gill IS (2008) Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol 54: 133-140.
2. Barlow L, Westergren K, Holmberg L, Talbäck M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48: 27-33.
3. Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J (2012) Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry. Ann Oncol 23: 395-401.
4. Swedish National Board of Health and Welfare, 2009. Cancer Incidence in Sweden 2009. Available at http://www.socialstyrelsen.se/Lists/Artikelkatalog/ Attachments/18204/2010-12-17.pdfaccessed 31 August 2011.
5. Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185: 60-66.
6. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1: CD001425.
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134. (Pubitemid 46089673)
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009a) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318.
9. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM (2009b) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1280-1289.
10. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171: 1071-1076. (Pubitemid 38327529)
11. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10: 757-763.
12. Heng DY, Chi KN, Murray N, Jin T, Garcia JA, Bukowski RM, Rini BI, Kollmannsberger C (2009) A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 115: 776-783.
13. Heng DY, Xie W, Bjarnason GA, Vaishampayan UN, Donskov F, Wood L, Knox JJ, Tan M, Kollmannsberger CK, Rini BI, Choueiri TK (2010) A unified prognostic model for first-and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): results from a large international study. J Clin Oncol 28: 15s suppl; abstr 4523.
14. Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F, Groschek M, Blumenstengel K, Pühse G, Steiner T (2011) Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol 29: 361-366.
15. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC. European Association of Urology Guideline Group (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58: 398-406.
16. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB (2011) NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 9: 960-977.
17. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296. (Pubitemid 34032623)
18. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
19. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124. (Pubitemid 46089672)
20. Swedish National Board of Health and Welfare (2011) Quality and Efficiency in Swedish Cancer Care-Regional comparisons 2011. Available at http://www.socialstyrelsen.se/publikationer2012/2012-3-15.
21. Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E (2011) Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 108(8 Pt 2): E250-E257.
22. Shek D, Tomlinson B, Brown M, Brunson A, Pan CX, Lara Jr PN (2012) Epidemiological trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28, 252 patients. Clin Genitourin Cancer 10: 93-98.
23. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller Jr WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM. ARCCS Study Investigators (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116: 1272-1280.
24. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M (2007) The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16: 726-735. (Pubitemid 47180362)
25. Woldrich JM, Mallin K, Ritchey J, Carroll PR, Kane CJ (2008) Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993-2004. J Urol 179: 1709-1713.